Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Advances in Clinical Genomics Profiling » ADx Healthcare to Launch Alzheimer's Polygenic Risk Test Through Japanese Clinic

ADx Healthcare to Launch Alzheimer's Polygenic Risk Test Through Japanese Clinic

Mar 02, 2020
|
staff reporter

NEW YORK – Alzheimer's disease testing firm ADx Healthcare said today that it has partnered with Osaka, Japan-based Nakanoshima Clinic and Ixlayer, a San Francisco health IT company, to launch a polygenic-risk score for early detection of Alzheimer’s disease in Japan.

The test, called GenoRisk, assays 32 genetic loci, with results analyzed and interpreted by ADx Healthcare's medical team. According to the firm's CEO Steve Booth, the panel included both risk-associated and protective genes that influence Alzheimer's disease risk.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Free of Influence

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

Avoiding the MARCH1 to 1-Mar Change

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

Nature Papers Reveal Tuatara Genome, Cell Populations Involved in Lupus

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

Overlooked Expertise

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Molecular Diagnostics

  1. Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

  2. Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing

    Premium

  3. Invitae Q2 Revenues Decrease 14 Percent but Beat Street Estimate

  4. Qiagen Q2 Revenues Soar 16 Percent on Coronavirus Testing Product Sales

  5. Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.